Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan and Nivolumab with FOLFIRINOX and SBRT in Localized Pancreatic Cancer
NCT03563248Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2018
- Primary completion
- Feb 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of losartan, nivolumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Massachusetts General Hospital. Started Aug 2018; status: active, not recruiting.
02
Drugs
losartannivolumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03563248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03563248.